If there is any real news, I’ve live-blog it. Recall that on January 24, 2011, while maintaining its overweight rating generally, Barclays (recently, an indirect holder of over 5% of all of Merck’s outstanding stock) lowered its 12 month price target from $43 back to $41 — just $1 over where Barclays’ target was one year ago.
So, its own views are — at best. . . conflicted.
. . . .Luciano Rossetti, M.D., Merck’s senior vice president, global scientific strategy, is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference in Miami on March 16 at 8:30 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation. . . .
An archive of the presentation will be available at the same location. . . .
Do check back, tomorrow morning.